Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention.
- Author:
Xiao-Fang TANG
1
;
Chen HE
;
Jin-Qing YUAN
;
Xian-Min MENG
;
Yue-Jin YANG
;
Xue-Wen QIN
;
Shu-Bin QIAO
;
Hai-Bo LIU
;
Yong-Jian WU
;
Min YAO
;
Jue CHEN
;
Shi-Jie YOU
;
Yuan WU
;
Jian-Jun LI
;
Jun DAI
;
Ji-Lin CHEN
;
Run-Lin GAO
;
Zai-Jia CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; genetics; Coronary Disease; diagnosis; drug therapy; genetics; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; therapeutic use; Polymorphism, Single Nucleotide; Prognosis; Ticlopidine; analogs & derivatives; therapeutic use
- From: Chinese Journal of Cardiology 2011;39(7):617-620
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the impact of cytochrome P450 (CYP) 2C19 681G > A polymorphism on long-term prognosis of clopidogrel-treated Chinese patients after percutaneous coronary intervention (PCI).
METHODSBetween January 1, 2009 and August 31,2009, 267 patients with coronary heart disease who received PCI and treated with clopidogrel for 12 months were enrolled. CYP2C19 * 2 was detected by MALDI-TOF MS and patients were grouped into CYP2C19 * 1/ * 1 (n = 130) and CYP2C19 * 2 carriers group (n = 137). Follow-up was 12 months. The primary endpoint was angina recurrence, urgent coronary revascularization, acute myocardial infarction, stent thrombosis, death and the combined end points.
RESULTSBaseline data were similar between two groups (P > 0.05). Urgent coronary revascularization and the combined end points occurred more frequently in CYP2C19 * 2 carriers than in CYP2C19 * 1/* 1 patients (7.3% vs. 1.5% and 8.0% vs. 2.3% respectively, all P < 0.05). But incidence of angina recurrence, acute myocardial infarction, stent thrombosis and death was similar between two groups (all P > 0.05). Hazard risk of 1 year cumulative survival of CYP2C19 * 2 carriers group was significantly higher than CYP2C19 * 1/ * 1 group after PCI ( HR = 3.59, 95% CI: 1.02 - 12.87, P < 0.05).
CONCLUSIONCYP2C19 681G > A polymorphism is a determinant of prognosis in coronary heart disease patients receiving chronic clopidogrel treatment after PCI.
